KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Short term Debt: 2018-2024

Historic Short term Debt for Royalty Pharma (RPRX) over the last 6 years, with Dec 2024 value amounting to $997.8 million.

  • Royalty Pharma's Short term Debt fell 61.88% to $380.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $380.0 million, marking a year-over-year decrease of 61.88%. This contributed to the annual value of $997.8 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, Royalty Pharma's Short term Debt is $997.8 million, which was up 0.03% from $997.5 million recorded in FY2022.
  • Royalty Pharma's 5-year Short term Debt high stood at $997.8 million for FY2024, and its period low was $107.9 million during FY2021.
  • Its 2-year average for Short term Debt is $997.6 million, with a median of $997.6 million in 2022.
  • In the last 5 years, Royalty Pharma's Short term Debt slumped by 55.19% in 2020 and then skyrocketed by 824.19% in 2022.
  • Yearly analysis of 4 years shows Royalty Pharma's Short term Debt stood at $126.4 million in 2020, then dropped by 14.59% to $107.9 million in 2021, then spiked by 824.19% to $997.5 million in 2022, then reached $997.8 million in 2024.